133217-92-2

Basic information

• Product Name: Diethyl-carbaMic Acid ChloroMethyl Ester
• Synonyms: ChloroMethyl DiethylcarbaMate;Diethyl-carbaMic Acid ChloroMethyl Ester
• CAS NO: 133217-92-2
• Molecular Formula: C₆H₁₂ClNO₂
• Molecular Weight: 165.61798
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 133217-92-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 190.4±19.0 °C(Predicted)
• Appearance: /
• Density: 1.106±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator, Under Inert Atmosphere
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• PKA: -1.55±0.70(Predicted)
• CAS DataBase Reference: Diethyl-carbaMic Acid ChloroMethyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: Diethyl-carbaMic Acid ChloroMethyl Ester(133217-92-2)
• EPA Substance Registry System: Diethyl-carbaMic Acid ChloroMethyl Ester(133217-92-2)

Safety Data

• Hazardous Substances Data: 133217-92-2(Hazardous Substances Data)

Usage

Chemical Properties

Clear Pale Yellow Oil

Uses

Intermediates in prodrug synthesis.

Upstream product

• 22128-62-7 carbonochloridic acid, chloromethyl ester 
• 109-89-7 diethylamine 

Downstream Products

• 872700-96-4 diethyl-carbamic acid 4-(3,5-bis-trifluoromethyl-phenyl)-[1,2,3]triazol-1-ylmethyl ester 
• 872700-93-1 diethyl-carbamic acid 4-(2-trifluoromethyl-phenyl)-[1,2,3]triazol-1-ylmethyl ester 
• 872700-97-5 diethyl-carbamic acid 4-(1-hydroxy-cyclohexyl)-[1,2,3]triazol-1-ylmethyl ester 
• 872700-94-2 diethyl-carbamic acid 4-(2-nitro-phenyl)-[1,2,3]triazol-1-ylmethyl ester 
• 872700-89-5 diethyl-carbamic acid 4-(4-methoxy-phenyl)-[1,2,3]triazol-1-ylmethyl ester 
• 872700-91-9 diethyl-carbamic acid 4-(4-amino-phenyl)-[1,2,3]triazol-1-ylmethyl ester 
• 872700-90-8 diethyl-carbamic acid 4-phenyl-[1,2,3]triazol-1-ylmethyl ester 

Relevant articles and documents

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.

Interleukin-4 gene expression inhibitors

This invention discloses and claims a class of indole and benzo(b)thiophene derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. The compounds of this invention are defined by the Formula (I): wherein X, Y, Z, R1, R2 and R3 are as defined in the specification; or a pharmaceutically acceptable salt thereof. In preferred embodiments of this invention it is also disclosed and claimed that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.